A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients

Simple item page
dc.contributor.authorSoltani, Saberen_US
dc.contributor.authorZakeri, Amir Mohammaden_US
dc.contributor.authorKarimi, Mohammad Rezaen_US
dc.contributor.authorRezayat, Sara Akhavanen_US
dc.contributor.authorAnbaji, Fateme Zomorodien_US
dc.contributor.authorTabibzadeh, Alirezaen_US
dc.contributor.authorYousefi, Parastooen_US
dc.contributor.authorZakeri, Arminen_US
dc.contributor.authorJafarpour, Alien_US
dc.contributor.authorNorouzi, Mehdien_US
dc.contributor.authorErfani, Yousefen_US
dc.contributor.authorPoortahmasebi, Vahdaten_US
dc.date.accessioned2020-11-18T10:30:26Z
dc.date.available2020-11-18T10:30:26Z
dc.date.issued2020-05
dc.description.abstractBackground:In December 2019, the pneumonia outbreak reported in Wuhan, Hubei Province, China. WHO introduced a novel coronavirus and the virus named Severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) in January 2020. There are not any specific antiviral agents for coronavirus disease 19 (COVID‐19). Objective:Our review aimed to discuss treatment options and the efficacy of currently prescribed drugs and supportive care in COVID‐19 patients. Study Design:A literature review of the articles in the Web of Science, PubMed, Scopus and EMBASE conducted. Results: Lopinavir/ritonavir combination was the most frequently used drug, followed by Arbidol and Oseltamivir and Methylprednisolone. Lopinavir/Ritonavir outcome showed the fever and respiratory infection improve in day two and day eight, respectively. Also, negative PCR of SARS‐CoV‐2 in days six and 7day was seen and finally these patients discharged in 10 days. Conclusions: Lopinavir/Ritonavir was the most improving administrated antiviral combination, which might be a good option for COVID-19 due to its availability. Although supportive care such as O2supplementary and IV fluid therapy has improved outcomes. There are not evidence forsuggesting a new treatment or a new drug, which mean the necessity of further investigations for drug research in a clinical trial for a conclusion about the optimum treatmenten_US
dc.identifier.affiliationsDepartment of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.identifier.affiliationsResearch Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran.en_US
dc.identifier.affiliationsStudents’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.identifier.affiliationsPediatric Surgery Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iranen_US
dc.identifier.affiliationsDepartment of Health Care Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iranen_US
dc.identifier.affiliationsDepartmentof Cell and Molecular Biology, School of Biology College of Science, University of Tehran, Tehran, Iranen_US
dc.identifier.affiliationsDepartment of Virology, Iran University of Medical Sciences, Tehran, Iranen_US
dc.identifier.affiliationsDepartment of Hematology, Faculty of Medical Sciences, Tarbiat Modares University,Tehran, Iranen_US
dc.identifier.affiliationsDepartment of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University Medical Sciences, Tehran, Iranen_US
dc.identifier.affiliationsInfectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iranen_US
dc.identifier.affiliationsLiver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iranen_US
dc.identifier.affiliationsDepartment of Bacteriology and Virology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.en_US
dc.identifier.citationSoltani Saber, Zakeri Amir Mohammad, Karimi Mohammad Reza, Rezayat Sara Akhavan, Anbaji Fateme Zomorodi, Tabibzadeh Alireza, Yousefi Parastoo, Zakeri Armin, Jafarpour Ali, Norouzi Mehdi, Erfani Yousef, Poortahmasebi Vahdat. A Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patients. Journal of Pharmaceutical Research International. 2020 May; 32(7): 13-25en_US
dc.identifier.issn2456-9119
dc.identifier.issn2231-2919
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/215987
dc.languageenen_US
dc.publisherSCIENCEDOMAIN internationalen_US
dc.relation.issuenumber7en_US
dc.relation.volume32en_US
dc.source.urihttps://doi.org/10.9734/JPRI/2020/v32i730455en_US
dc.subjectCoronavirusen_US
dc.subjectSARS virusen_US
dc.subjectsevere acute respiratory syndrome-related coronavirus 2en_US
dc.subjectCOVID-19en_US
dc.subjectantiviral agentsen_US
dc.subjectdrug therapyen_US
dc.subjecttherapeutics.en_US
dc.titleA Systematic Literature Review of Current Therapeutic Approaches for COVID-19 Patientsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jpri2020v32n7p13.pdf
Size:
365.53 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmaceutical Research International